Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines

Area of Science:

• Cardiovascular Medicine
• Health Disparities Research
• Clinical Pharmacology

Background:

• Hypertension (HTN) disproportionately affects Black populations, leading to significant cardiovascular, cerebrovascular, and renal complications.
• Racial disparities in health outcomes in the US are notably influenced by hypertension prevalence and severity.
• Clinical practice guidelines (CPGs) for HTN management are evolving, with recent US guidelines incorporating race more explicitly.

Purpose of the Study:

• To critically evaluate the implications of using race in hypertension CPGs.
• To review the evidence base supporting the inclusion of race in HTN treatment algorithms.
• To provide practical considerations for managing hypertension in Black patients.

Main Methods:

• Literature review of current hypertension clinical practice guidelines.
• Analysis of research on race as a predictor of therapeutic response to antihypertensive medications.
• Synthesis of evidence regarding the rationale and justification for race-based treatment recommendations.

Main Results:

• Recent hypertension CPGs increasingly emphasize race in treatment algorithms.
• Emerging clinical research questions the validity of using race as a proxy for drug response.
• The evidence supporting race-based hypertension management requires careful scrutiny.

Conclusions:

• The use of race in hypertension CPGs warrants critical examination due to potential inaccuracies in predicting treatment efficacy.
• Further research is needed to refine hypertension management strategies for Black individuals, moving beyond race as a sole determinant.
• Practical approaches to hypertension treatment in Black patients should consider individual variability and evidence-based alternatives to race-based protocols.